BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Tovo CV, de Mattos AZ, Coral GP, Sartori GDP, Nogueira LV, Both GT, Villela-Nogueira CA, de Mattos AA. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. World J Gastroenterol 2023; 29(2): 343-356 [PMID: 36687125 DOI: 10.3748/wjg.v29.i2.343]
URL: https://www.wjgnet.com/1948-5182/full/v29/i2/343.htm
Number Citing Articles
1
Madalina-Gabriela Taru, Monica Lupsor-Platon. Exploring Opportunities to Enhance the Screening and Surveillance of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease (NAFLD) through Risk Stratification Algorithms Incorporating Ultrasound ElastographyCancers 2023; 15(16): 4097 doi: 10.3390/cancers15164097
2
Cornelius J Fernandez, Lakshmi Nagendra, Joseph M Pappachan. Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global ActiontouchREVIEWS in Endocrinology 2023; 20(1): 1 doi: 10.17925/EE.2023.20.1.1
3
Junyu Wu, Hor-Yue Tan, Yau-Tuen Chan, Yuanjun Lu, Zixin Feng, Hongchao Yuan, Cheng Zhang, Yibin Feng, Ning Wang. PARD3 drives tumorigenesis through activating Sonic Hedgehog signalling in tumour-initiating cells in liver cancerJournal of Experimental & Clinical Cancer Research 2024; 43(1) doi: 10.1186/s13046-024-02967-3
4
Júlia Pauli De Cól, Enzo Pereira de Lima, Fernanda Moris Pompeu, Adriano Cressoni Araújo, Ricardo de Alvares Goulart, Marcelo Dib Bechara, Lucas Fornari Laurindo, Nahum Méndez-Sánchez, Sandra Maria Barbalho. Underlying Mechanisms behind the Brain–Gut–Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An UpdateInternational Journal of Molecular Sciences 2024; 25(7): 3694 doi: 10.3390/ijms25073694
5
Gianni TESTINO, Rinaldo PELLICANO. Corrected and republished from: Metabolic associated liver diseasePanminerva Medica 2023; 65(3) doi: 10.23736/S0031-0808.23.04850-4